Clinical Trial Update: A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a recombinant HIV-1 Tat protein vaccine in HIV-infected, anti-Tat negative, ART-treated adults; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• HIV-1 Tat protein vaccine (HIV-1 Tat protein vaccine)

Snippet

Sponsor: Barbara Ensoli, MD | Conditions: HIV Infections | Phase 2 | Status: COMPLETED